Lilly Sales Swing Back As Pandemic, Loss Of Exclusivity Pressures Recede
Diabetes, Immunology, Oncology Lead 28% Sales Jump
The drug maker is looking ahead to potentially big approvals of donanemab for Alzheimer’s disease and Mounjaro for obesity by the end of the year.
